Track sentiment, discussions and live quotes, post ideas and see what real traders are doing

A sharp rally and unusually heavy bullish call activity ahead of earnings are driving attention, with bulls pointing to Snaps Specs AR glasses and a proposal to sell an outside stake in the unit as potential catalysts. Others question whether the enthusiasm can last, citing ad-market concerns and the risk that options-driven momentum fades.

Okta is drawing attention as cybersecurity shares rally on expectations that AI-related risks and AI-agent adoption will increase demand for identity protection and access controls. Traders are debating whether the AI-security growth narrative justifies the stocks sharp run, with some bullish on momentum and others warning about stretched valuations and a possible pullback.

American Express shares fell despite an earnings beat and raised profit outlook, as traders focused on plans to cut about 5% of the workforce and a slight revenue miss. Some see resilient spending and stronger guidance as positives, while others question the outlook amid restructuring and rising expenses.

Attention centers on the anticipated CTX310 Phase 1b data presentation at the AHA, which traders see as a key test of CRISPR Therapeutics in-vivo gene-editing program for severe hypertriglyceridemia. The CFO transition has raised concern among some holders, though others point to the stated orderly handoff and no reported disagreements; frustration with CRSPs prolonged range-bound trading is also widespread.

BlackSkys expanded seven-figure Gen-3 contract with an international defense partner is drawing attention, but traders are debating why the shares remain weak despite contract wins. Some see the deals as evidence of execution, while others are focused on the steep decline and upcoming Q3 results.

TG Therapeutics early Phase 1 azer-cel results in progressive multiple sclerosis are drawing attention, with traders highlighting the encouraging safety profile and disability stabilization or improvement while noting the study is small and preliminary. The community is divided between viewing the data as a promising new growth opportunity and disappointment that the stock reaction has been muted.

Published NEST Phase 2 results for Agenuss BOT+BAL combination in early-stage colorectal cancer are drawing attention, with supporters highlighting tumor responses and no observed recurrences in the small study cohorts. Skeptics counter that the results are from nonrandomized trials and point to delays in the planned Phase 3 program, alongside concerns about dilution and management execution.

Cybersecurity shares rallied on an Evercore channel-partner survey suggesting enterprise security budgets are firming, alongside vulnerability headlines that heightened concerns about AI-driven threats. Traders highlighted PANWs sector strength and rebound, while some questioned whether the security-spending outlook justifies its elevated valuation.

Mercks partnership with Moderna is drawing attention after their personalized melanoma vaccine, combined with Keytruda, met Phase 3 endpoints; traders are weighing the clinical promise against results that fell short of some expectations. Discussion also questions the treatments cost and manufacturing complexity, though Mercks CEO has expressed confidence in its commercial scalability.

Anticipation of Anthropics IPO prospectus and possible S-1 filing is driving attention to DXYZ as a public-market proxy for its private-company holdings. Traders expect the IPO and updated NAV estimates to support a re-rating, while skeptics point to uncertainty over timing and valuation and DXYZs persistent discount to reported NAV.